董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Geoff Pardo | 男 | Director | 48 | 未披露 | 未持股 | 2020-05-26 |
| William Hoffman | 男 | Chief Executive Officer, President and Director | 52 | 96.34万美元 | 未持股 | 2020-05-26 |
| Donald Milder | 男 | Chair of the Board | 65 | 未披露 | 未持股 | 2020-05-26 |
| Robert Rosenbluth | 男 | Director | 74 | 4.07万美元 | 未持股 | 2020-05-26 |
| Kirk Nielsen | 男 | Director | 46 | 未披露 | 未持股 | 2020-05-26 |
| Brian Cox | 男 | Director | 62 | 6.15万美元 | 未持股 | 2020-05-26 |
| Cynthia Lucchese | 女 | Director | 59 | 16.32万美元 | 未持股 | 2020-05-26 |
| Jonathan Root | -- | Director | 60 | 未披露 | 未持股 | 2020-05-26 |
| Catherine Szyman | 女 | Director | 53 | 16.32万美元 | 未持股 | 2020-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Hoffman | 男 | Chief Executive Officer, President and Director | 52 | 96.34万美元 | 未持股 | 2020-05-26 |
| Mitchell Hill | 男 | Chief Financial Officer | 61 | 64.10万美元 | 未持股 | 2020-05-26 |
| Andrew Hykes | 男 | Chief Commercial Officer | 47 | 65.36万美元 | 未持股 | 2020-05-26 |
| Thomas Tu | 男 | Chief Medical Officer | 47 | 未披露 | 未持股 | 2020-05-26 |
董事简历
中英对照 | 中文 | 英文- Geoff Pardo
-
Geoff Pardo自2020年7月以来一直担任我们的董事会成员。Pardo先生自2011年以来一直担任Gilde梦百合的合伙人。此前，他曾担任Spray Venture Partners公司的合伙人（2004年至2011年）。他也曾担任Facet Solutions公司（脊柱植入公司，专注于治疗腰椎管狭窄症）的总裁兼首席执行官（从2007年到2011年公司出售给Globus Medical公司）。他目前担任以下上市医疗设备公司的董事会成员:InariMedical，Inc.和Vapotherm，Inc.他曾任职于以下上市公司的董事会:Axonics ModulationTechnologies，Inc.公司（医疗设备公司）。Pardo先生在布朗大学（Brown University）获得文学学士学位，并在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Geoff Pardo has served as one of our directors since July 2016 and as a Partner at Gilde Healthcare Partners B.V. “Gilde”, a specialized European healthcare investor, since 2011. Previously, he was a Partner at Spray Venture Partners from 2004 to 2011 where he led investments in Cascade Ophthalmics (“Cascade”), Interlace Medical Inc., Solace Therapeutics, Inc. (“Solace”) and TearScience. Mr. Pardo also served as President & CEO of Facet Solutions Inc., a spinal implant company focused on treating lumbar spinal stenosis, until the company was sold to Globus Medical, Inc. in 2011. He also has worked at Cardinal Partners as an Associate leading their investing activities in the medical device sector. Mr. Pardo represents Gilde as a member of the boards of directors of Ablative Solutions, Inc., Eargo, Inc., Inari Medical, Inc., Vesper Medical, Inc. He previously served on the boards of directors of Axonics Modulation Technologies, Inc., BionX Medical Technologies, Inc., Cascade, Inova Labs Inc., Solace, TearScience and Vapotherm, Inc. He graduated with a B.A. in History from Brown University and an M.B.A. from The Wharton School of the University of Pennsylvania. - Geoff Pardo自2020年7月以来一直担任我们的董事会成员。Pardo先生自2011年以来一直担任Gilde梦百合的合伙人。此前，他曾担任Spray Venture Partners公司的合伙人（2004年至2011年）。他也曾担任Facet Solutions公司（脊柱植入公司，专注于治疗腰椎管狭窄症）的总裁兼首席执行官（从2007年到2011年公司出售给Globus Medical公司）。他目前担任以下上市医疗设备公司的董事会成员:InariMedical，Inc.和Vapotherm，Inc.他曾任职于以下上市公司的董事会:Axonics ModulationTechnologies，Inc.公司（医疗设备公司）。Pardo先生在布朗大学（Brown University）获得文学学士学位，并在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Geoff Pardo has served as one of our directors since July 2016 and as a Partner at Gilde Healthcare Partners B.V. “Gilde”, a specialized European healthcare investor, since 2011. Previously, he was a Partner at Spray Venture Partners from 2004 to 2011 where he led investments in Cascade Ophthalmics (“Cascade”), Interlace Medical Inc., Solace Therapeutics, Inc. (“Solace”) and TearScience. Mr. Pardo also served as President & CEO of Facet Solutions Inc., a spinal implant company focused on treating lumbar spinal stenosis, until the company was sold to Globus Medical, Inc. in 2011. He also has worked at Cardinal Partners as an Associate leading their investing activities in the medical device sector. Mr. Pardo represents Gilde as a member of the boards of directors of Ablative Solutions, Inc., Eargo, Inc., Inari Medical, Inc., Vesper Medical, Inc. He previously served on the boards of directors of Axonics Modulation Technologies, Inc., BionX Medical Technologies, Inc., Cascade, Inova Labs Inc., Solace, TearScience and Vapotherm, Inc. He graduated with a B.A. in History from Brown University and an M.B.A. from The Wharton School of the University of Pennsylvania.
- William Hoffman
-
William Hoffman自2015年2月以来一直担任我们的首席执行官兼总裁，并担任我们的董事会成员。Hoffman之前从2008年5月到2014年7月被Medtronic plc（Medtronic）收购，担任Visualase，Inc.（一家专注于MRI引导激光的私人公司）首席执行官。在此之前，Hoffman先生从2006年4月到2007年11月是Rubicor Medical，Inc.的首席运营官，该公司是一家私人公司，专注于微创乳腺活检和肿块切除术技术。Hoffman从2003年7月到2006年2月担任Foxhollow Technologies，Inc.（一家制造用于治疗外周动脉疾病的医疗设备的私营公司）销售主管，然后担任销售Vice President。Hoffman先生目前任职于两家私人公司的董事会:Monteris Medical，Inc.和4C Medical Group。Hoffman先生在迪金森学院（Dickinson College）获得文学学士学位。
William Hoffman has served as our Chief Executive Officer and President and as a member of our board of directors since February 2015. Mr. Hoffman previously served as Chief Executive Officer at Visualase, Inc., a private company focusing on MRI-guided lasers, from May 2008 until its acquisition by Medtronic PLC, or Medtronic, in July 2014. Prior to this, Mr. Hoffman was the Chief Operating Officer of Rubicor Medical, Inc., a private company focusing on minimally invasive breast biopsy and lumpectomy technology, from April 2006 to November 2007. From July 2003 to February 2006 Mr. Hoffman served as Director of Sales and then the Vice President of Sales at FoxHollow Technologies, Inc, a private company that makes medical devices used to treat peripheral artery disease. Mr. Hoffman currently serves on the board of directors of two private companies: Monteris Medical, Inc. and 4C Medical Group. Mr. Hoffman received a B.A. from Dickinson College. - William Hoffman自2015年2月以来一直担任我们的首席执行官兼总裁，并担任我们的董事会成员。Hoffman之前从2008年5月到2014年7月被Medtronic plc（Medtronic）收购，担任Visualase，Inc.（一家专注于MRI引导激光的私人公司）首席执行官。在此之前，Hoffman先生从2006年4月到2007年11月是Rubicor Medical，Inc.的首席运营官，该公司是一家私人公司，专注于微创乳腺活检和肿块切除术技术。Hoffman从2003年7月到2006年2月担任Foxhollow Technologies，Inc.（一家制造用于治疗外周动脉疾病的医疗设备的私营公司）销售主管，然后担任销售Vice President。Hoffman先生目前任职于两家私人公司的董事会:Monteris Medical，Inc.和4C Medical Group。Hoffman先生在迪金森学院（Dickinson College）获得文学学士学位。
- William Hoffman has served as our Chief Executive Officer and President and as a member of our board of directors since February 2015. Mr. Hoffman previously served as Chief Executive Officer at Visualase, Inc., a private company focusing on MRI-guided lasers, from May 2008 until its acquisition by Medtronic PLC, or Medtronic, in July 2014. Prior to this, Mr. Hoffman was the Chief Operating Officer of Rubicor Medical, Inc., a private company focusing on minimally invasive breast biopsy and lumpectomy technology, from April 2006 to November 2007. From July 2003 to February 2006 Mr. Hoffman served as Director of Sales and then the Vice President of Sales at FoxHollow Technologies, Inc, a private company that makes medical devices used to treat peripheral artery disease. Mr. Hoffman currently serves on the board of directors of two private companies: Monteris Medical, Inc. and 4C Medical Group. Mr. Hoffman received a B.A. from Dickinson College.
- Donald Milder
-
Donald Milder自2011年9月起担任董事会成员，自2019年12月起担任董事会主席。他于1999年共同创立Versant Venture Management公司（Versant公司），在那里他一直担任董事总经理（公司创立以来）。Versant是一家风险投资公司，投资于医疗设备、生物技术、生命科学、制药和梦百合部门。此前，他曾担任CPVP Management LP的董事总经理（1989年8月至1999年11月），在那里他负责他们的梦百合投资。在此之前，Milder先生从1984年到1989年是输液系统公司（Influition Systems Corporation）的首席执行官。他目前担任Eclipse Regenesis，Inc.、Okami、NeoSeq Ltd.和Ceres Foundation的董事会成员。Milder先生在联合学院（Union College）获得学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Donald Milder has served as a member of our board of directors since September 2011 and as its Chair since December 2019. In 1999 Mr. Milder co-founded Versant Venture Management, LLC, or Versant, where he has been a Managing Director since its inception. Versant is a venture capital firm that invests in medical devices, biotechnology, life science, pharmaceuticals and healthcare sectors. Previously, Mr. Milder was a Managing Director with CPVP Management LP from August 1989 to November 1999 where he was responsible for their healthcare investments. Prior to this, Mr. Milder was the Chief Executive Officer of Infusion Systems Corporation from 1984 to 1989. He currently serves as a board member for Eclipse Regenesis, Inc., Okami, NeoSeq Ltd. and Ceres Foundation. Mr. Milder received a B.A. from Union College and an M.B.A. from Harvard Business School. - Donald Milder自2011年9月起担任董事会成员，自2019年12月起担任董事会主席。他于1999年共同创立Versant Venture Management公司（Versant公司），在那里他一直担任董事总经理（公司创立以来）。Versant是一家风险投资公司，投资于医疗设备、生物技术、生命科学、制药和梦百合部门。此前，他曾担任CPVP Management LP的董事总经理（1989年8月至1999年11月），在那里他负责他们的梦百合投资。在此之前，Milder先生从1984年到1989年是输液系统公司（Influition Systems Corporation）的首席执行官。他目前担任Eclipse Regenesis，Inc.、Okami、NeoSeq Ltd.和Ceres Foundation的董事会成员。Milder先生在联合学院（Union College）获得学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Donald Milder has served as a member of our board of directors since September 2011 and as its Chair since December 2019. In 1999 Mr. Milder co-founded Versant Venture Management, LLC, or Versant, where he has been a Managing Director since its inception. Versant is a venture capital firm that invests in medical devices, biotechnology, life science, pharmaceuticals and healthcare sectors. Previously, Mr. Milder was a Managing Director with CPVP Management LP from August 1989 to November 1999 where he was responsible for their healthcare investments. Prior to this, Mr. Milder was the Chief Executive Officer of Infusion Systems Corporation from 1984 to 1989. He currently serves as a board member for Eclipse Regenesis, Inc., Okami, NeoSeq Ltd. and Ceres Foundation. Mr. Milder received a B.A. from Union College and an M.B.A. from Harvard Business School.
- Robert Rosenbluth
-
Robert Rosenbluth自2011年9月起担任董事会成员，2011年9月至2019年12月担任董事会主席，2011年9月至2014年12月担任首席执行官兼总裁。Rosenbluth博士是我们公司的联合创始人。此前，他曾担任Sequent Medical公司的联席创始人兼董事会主席（从2007年5月到2016年7月被Terumo Medical Corporation收购），以及首席执行官兼总裁（从2007年5月到2010年2月）。在此之前，Rosenbluth博士从1997年11月开始担任Microvention的联合创始人兼董事会主席，直到2006年3月它被Terumo Medical Corporation收购，从1997年11月到2002年9月担任首席执行官兼总裁。Rosenbluth博士目前在Inceptus Medical LLC（Inceptus，一家私人医疗设备公司孵化器）的董事会任职，并担任Okami Medical Inc.（Okami，一家专注于开发旨在堵塞周围血管的医疗设备的私人公司。Rosenbluth博士在哥伦比亚大学（Columbia University）获得学士学位，在加州大学伯克利分校（University of California，Berkeley）获得硕士学位和博士学位。Rosenbluth博士希望在本次发行完成之前辞去我们的董事会职务。
Robert Rosenbluth has served as a member of our board of directors since September 2011 as Chair of the board of directors from September 2011 until December 2019 and as Chief Executive Officer and President from September 2011 until December 2014. Dr. Rosenbluth is a co-founder of our company. Prior to this, he was the co-founder and chairman of the board of directors of Sequent Medical from May 2007 until its acquisition by Terumo Medical Corporation in July 2016 and Chief Executive Officer and President from May 2007 until February 2010. Prior to this, Dr. Rosenbluth was the co-founder and chairman of the board of directors MicroVention from November 1997 until it was acquired by Terumo Medical Corporation in March 2006 and Chief Executive Officer and President from November 1997 until September 2002. Dr. Rosenbluth currently serves on the board of Inceptus Medical LLC, or Inceptus, a private medical device company incubator, and as chairman of the board of directors, Chief Executive Officer and President of Okami Medical Inc., or Okami, a private company focused on developing medical devices designed to occlude peripheral vessels. Dr. Rosenbluth received his B.S. from Columbia University and M.S. and Ph.D. from University of California, Berkeley. Dr. Rosenbluth expects to resign from our board of directors prior to the closing of this offering. - Robert Rosenbluth自2011年9月起担任董事会成员，2011年9月至2019年12月担任董事会主席，2011年9月至2014年12月担任首席执行官兼总裁。Rosenbluth博士是我们公司的联合创始人。此前，他曾担任Sequent Medical公司的联席创始人兼董事会主席（从2007年5月到2016年7月被Terumo Medical Corporation收购），以及首席执行官兼总裁（从2007年5月到2010年2月）。在此之前，Rosenbluth博士从1997年11月开始担任Microvention的联合创始人兼董事会主席，直到2006年3月它被Terumo Medical Corporation收购，从1997年11月到2002年9月担任首席执行官兼总裁。Rosenbluth博士目前在Inceptus Medical LLC（Inceptus，一家私人医疗设备公司孵化器）的董事会任职，并担任Okami Medical Inc.（Okami，一家专注于开发旨在堵塞周围血管的医疗设备的私人公司。Rosenbluth博士在哥伦比亚大学（Columbia University）获得学士学位，在加州大学伯克利分校（University of California，Berkeley）获得硕士学位和博士学位。Rosenbluth博士希望在本次发行完成之前辞去我们的董事会职务。
- Robert Rosenbluth has served as a member of our board of directors since September 2011 as Chair of the board of directors from September 2011 until December 2019 and as Chief Executive Officer and President from September 2011 until December 2014. Dr. Rosenbluth is a co-founder of our company. Prior to this, he was the co-founder and chairman of the board of directors of Sequent Medical from May 2007 until its acquisition by Terumo Medical Corporation in July 2016 and Chief Executive Officer and President from May 2007 until February 2010. Prior to this, Dr. Rosenbluth was the co-founder and chairman of the board of directors MicroVention from November 1997 until it was acquired by Terumo Medical Corporation in March 2006 and Chief Executive Officer and President from November 1997 until September 2002. Dr. Rosenbluth currently serves on the board of Inceptus Medical LLC, or Inceptus, a private medical device company incubator, and as chairman of the board of directors, Chief Executive Officer and President of Okami Medical Inc., or Okami, a private company focused on developing medical devices designed to occlude peripheral vessels. Dr. Rosenbluth received his B.S. from Columbia University and M.S. and Ph.D. from University of California, Berkeley. Dr. Rosenbluth expects to resign from our board of directors prior to the closing of this offering.
- Kirk Nielsen
-
Kirk Nielsen自2011年9月以来一直担任我们的董事会成员。尼尔森先生自2019年1月起担任专注于医疗技术的投资公司Vensana Capital的管理合伙人，自2011年1月起担任专注于梦百合的风险投资公司Versant Ventures的董事总经理。他目前担任几家私人公司的董事会成员，包括:Metavention公司、Monteris Medical公司、Respicardia公司、Veran Medical Technologies公司。Mr.Nielsen在Harvard College获得A.B.，在Harvard Business School获得M.B.A.。
Kirk Nielsen has served as one of our directors since July 2020. Mr. Nielsen has been a Managing Partner at Vensana Capital, a medtech-focused investment firm, since January 2019 and a Managing Director of Versant Ventures, a healthcare-focused venture capital firm, since January 2011. He currently serves on the board of directors of public company Inari Medical, Inc. and as a board member for several private companies, including: Alleviant Medical, Metavention, Monteris Medical, and SpyGlass Ophthalmics. Mr. Nielsen received an A.B. from Harvard College and an M.B.A. from Harvard Business School. - Kirk Nielsen自2011年9月以来一直担任我们的董事会成员。尼尔森先生自2019年1月起担任专注于医疗技术的投资公司Vensana Capital的管理合伙人，自2011年1月起担任专注于梦百合的风险投资公司Versant Ventures的董事总经理。他目前担任几家私人公司的董事会成员，包括:Metavention公司、Monteris Medical公司、Respicardia公司、Veran Medical Technologies公司。Mr.Nielsen在Harvard College获得A.B.，在Harvard Business School获得M.B.A.。
- Kirk Nielsen has served as one of our directors since July 2020. Mr. Nielsen has been a Managing Partner at Vensana Capital, a medtech-focused investment firm, since January 2019 and a Managing Director of Versant Ventures, a healthcare-focused venture capital firm, since January 2011. He currently serves on the board of directors of public company Inari Medical, Inc. and as a board member for several private companies, including: Alleviant Medical, Metavention, Monteris Medical, and SpyGlass Ophthalmics. Mr. Nielsen received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
- Brian Cox
-
Brian Cox最初于2011年9月至2019年4月担任我们的董事会成员，然后于2020年4月再次担任至今。考克斯先生是我们公司的联合创始人，曾于2013年9月至2017年4月担任Vice President。他也是Inceptus和Okami的联合创始人，并分别自2011年和2016年成立以来担任两家公司的Vice President。在此之前，Cox先生是Sequent Medical的联合创始人、首席技术官和Vice President。自2016年5月起，Cox先生一直担任Okami的董事会成员。Cox先生是70多项已发行美国和国际专利的发明家。Cox先生在俄勒冈州立大学（Oregon State University）获得机械工程学士学位，并在佩珀代因大学（Pepperdine University）获得工商管理硕士学位。Cox先生希望在本次发行完成之前辞去我们的董事会职务。
Brian Cox first served as a member of our board of directors from September 2011 until April 2019 and then again in April 2020 to present. Mr. Cox is a co-founder of our company and previously served as Vice President from September 2013 to April 2017. He is also a co-founder of Inceptus and Okami and has served as a Vice President at both since their inception in 2011 and 2016 respectively. Prior to this, Mr. Cox was co-founder, Chief Technical Officer and Vice President of Sequent Medical. Since May 2016 Mr. Cox has served on the board of Okami. Mr. Cox is an inventor on over 70 issued U.S. and international patents. Mr. Cox received a B.S. in mechanical engineering from Oregon State University and an M.B.A. from Pepperdine University. Mr. Cox expects to resign from our board of directors prior to the closing of this offering. - Brian Cox最初于2011年9月至2019年4月担任我们的董事会成员，然后于2020年4月再次担任至今。考克斯先生是我们公司的联合创始人，曾于2013年9月至2017年4月担任Vice President。他也是Inceptus和Okami的联合创始人，并分别自2011年和2016年成立以来担任两家公司的Vice President。在此之前，Cox先生是Sequent Medical的联合创始人、首席技术官和Vice President。自2016年5月起，Cox先生一直担任Okami的董事会成员。Cox先生是70多项已发行美国和国际专利的发明家。Cox先生在俄勒冈州立大学（Oregon State University）获得机械工程学士学位，并在佩珀代因大学（Pepperdine University）获得工商管理硕士学位。Cox先生希望在本次发行完成之前辞去我们的董事会职务。
- Brian Cox first served as a member of our board of directors from September 2011 until April 2019 and then again in April 2020 to present. Mr. Cox is a co-founder of our company and previously served as Vice President from September 2013 to April 2017. He is also a co-founder of Inceptus and Okami and has served as a Vice President at both since their inception in 2011 and 2016 respectively. Prior to this, Mr. Cox was co-founder, Chief Technical Officer and Vice President of Sequent Medical. Since May 2016 Mr. Cox has served on the board of Okami. Mr. Cox is an inventor on over 70 issued U.S. and international patents. Mr. Cox received a B.S. in mechanical engineering from Oregon State University and an M.B.A. from Pepperdine University. Mr. Cox expects to resign from our board of directors prior to the closing of this offering.
- Cynthia Lucchese
-
Cynthia Lucchese自2019年11月以来一直担任我们的董事会成员。自2015年11月起，Lucchese女士一直担任Hulman&Company（一家赛车比赛和娱乐公司）的首席行政官兼首席财务官。在此之前，她曾于2008年1月至2014年3月担任Hillenbrand，Inc.的高级副总裁兼首席财务官，该公司是一家上市公司，拥有多个品牌，服务于全球多个行业。Lucchese女士拥有医疗设备和生命科学公司的经验，包括Guidant，Thoratec和Eli Lilly。Lucchese女士目前在两家上市公司的董事会任职。自2014年7月以来，她一直担任IntersectEnt，Inc.（一家公开上市的医疗器械公司）的董事会成员、审计委员会主席以及提名和公司治理委员会成员。此外，自2015年5月起，Lucchese女士一直担任Hanger，Inc.的董事会成员，该公司是一家提供矫形和修复产品以及患者护理的上市公司。Lucchese女士于2017年11月成为Hanger&8217；的审计委员会成员，此前曾担任薪酬委员会成员。Lucchese女士也是BVI International，Inc.（一家私人拥有的全球眼科设备公司）的董事会成员和审计委员会主席。Lucchese女士拥有印第安纳大学凯利商学院（Indiana University，Kelley School of Business）会计学士学位和工商管理硕士学位。
Cynthia Lucchese has served as a member of our board of directors since November 2019. Since November 2015 Ms. Lucchese has been the Chief Administrative Officer and Chief Financial Officer of Hulman & Company, a motorsports competition and entertainment company. Prior to this she was the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a public company with multiple brands that serve a range of industries across the globe, from January 2008 until March 2014. Ms. Lucchese has experience with medical device and life sciences companies, including Guidant, Thoratec and Eli Lilly. Ms. Lucchese currently serves on the board of two public companies. Since July 2014 she has been a board member and serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of Intersect ENT, Inc., a publicly traded medical device company. Additionally, Ms. Lucchese has been a board member of Hanger, Inc., a public company that delivers orthotic and prosthetic products and patient care, since May 2015. Ms. Lucchese became a member of Hanger’s Audit Committee in November 2017 and previously was a member of the Compensation Committee. Ms. Lucchese is also a board member and Audit Committee Chair for BVI International, Inc., a privately owned global ophthalmic device company. Ms. Lucchese has a B.S. in accounting and an M.B.A. from Indiana University, Kelley School of Business. - Cynthia Lucchese自2019年11月以来一直担任我们的董事会成员。自2015年11月起，Lucchese女士一直担任Hulman&Company（一家赛车比赛和娱乐公司）的首席行政官兼首席财务官。在此之前，她曾于2008年1月至2014年3月担任Hillenbrand，Inc.的高级副总裁兼首席财务官，该公司是一家上市公司，拥有多个品牌，服务于全球多个行业。Lucchese女士拥有医疗设备和生命科学公司的经验，包括Guidant，Thoratec和Eli Lilly。Lucchese女士目前在两家上市公司的董事会任职。自2014年7月以来，她一直担任IntersectEnt，Inc.（一家公开上市的医疗器械公司）的董事会成员、审计委员会主席以及提名和公司治理委员会成员。此外，自2015年5月起，Lucchese女士一直担任Hanger，Inc.的董事会成员，该公司是一家提供矫形和修复产品以及患者护理的上市公司。Lucchese女士于2017年11月成为Hanger&8217；的审计委员会成员，此前曾担任薪酬委员会成员。Lucchese女士也是BVI International，Inc.（一家私人拥有的全球眼科设备公司）的董事会成员和审计委员会主席。Lucchese女士拥有印第安纳大学凯利商学院（Indiana University，Kelley School of Business）会计学士学位和工商管理硕士学位。
- Cynthia Lucchese has served as a member of our board of directors since November 2019. Since November 2015 Ms. Lucchese has been the Chief Administrative Officer and Chief Financial Officer of Hulman & Company, a motorsports competition and entertainment company. Prior to this she was the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a public company with multiple brands that serve a range of industries across the globe, from January 2008 until March 2014. Ms. Lucchese has experience with medical device and life sciences companies, including Guidant, Thoratec and Eli Lilly. Ms. Lucchese currently serves on the board of two public companies. Since July 2014 she has been a board member and serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of Intersect ENT, Inc., a publicly traded medical device company. Additionally, Ms. Lucchese has been a board member of Hanger, Inc., a public company that delivers orthotic and prosthetic products and patient care, since May 2015. Ms. Lucchese became a member of Hanger’s Audit Committee in November 2017 and previously was a member of the Compensation Committee. Ms. Lucchese is also a board member and Audit Committee Chair for BVI International, Inc., a privately owned global ophthalmic device company. Ms. Lucchese has a B.S. in accounting and an M.B.A. from Indiana University, Kelley School of Business.
- Jonathan Root
-
Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
Jonathan Root has served as a member of Edgewise Therapeutics, Inc.'s board of directors since August 2019. Dr. Root has served as the Managing Member of several U.S. Venture Partners' funds since January 1998. Dr. Root has served as a member of the board of directors of Silverback Therapeutics, Inc. since March 2020 and Inari Medical, Inc., a medical technology company focusing on treatment of large clots, since September 2011. Previously, Dr. Root has served as a board member for OncoMed Pharmaceuticals, Inc., a public pharmaceutical company developing cancer therapeutics, from August 2004 to April 2019. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received a A.B. in economics from Dartmouth College, a M.B.A. from Columbia Business School, and a M.D. from the University of Florida College of Medicine. - Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
- Jonathan Root has served as a member of Edgewise Therapeutics, Inc.'s board of directors since August 2019. Dr. Root has served as the Managing Member of several U.S. Venture Partners' funds since January 1998. Dr. Root has served as a member of the board of directors of Silverback Therapeutics, Inc. since March 2020 and Inari Medical, Inc., a medical technology company focusing on treatment of large clots, since September 2011. Previously, Dr. Root has served as a board member for OncoMed Pharmaceuticals, Inc., a public pharmaceutical company developing cancer therapeutics, from August 2004 to April 2019. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received a A.B. in economics from Dartmouth College, a M.B.A. from Columbia Business School, and a M.D. from the University of Florida College of Medicine.
- Catherine Szyman
-
Catherine Szyman，自2012年11月起一直担任美敦力公司的高级副总裁兼总裁。在此之前，从2009年8月至2012年11月，她担任糖尿病高级副总裁及总裁；从2008年4月至2009年8月，担任战略与创新高级副总裁；从2004年10月至2008年4月，担任心血管业务部血管内创新副总裁兼总经理。从1991年到2004年，她在美敦力公司担任过多个管理和领导职务，包括公司战略副总裁和血管业务财务部副总裁。
Catherine Szyman has served as a member of our board of directors since November 2019. Since January 2015 Ms. Szyman has been the Corporate Vice President of Critical Care at Edwards Lifesciences Corp., a public company specializing in artificial heart valves and hemodynamic monitoring. Prior to this, Ms. Szyman worked at Medtronic from August 1991 to December 2014 where she held a number of roles, including President of Global Diabetes, Vice President of Corporate Strategy and Business Developments, Vice President and General Manager for the endovascular business and Vice President of Finance for the vascular business. Ms. Szyman currently serves on the board of director of Endotronix, Inc., a private medical device company, Opus College of Business at the University of St. Thomas and the American Heart Association, a non-profit organization that funds cardiovascular medical research. Ms. Szyman has a B.A. from University of St. Thomas and an M.B.A. from Harvard Business School. - Catherine Szyman，自2012年11月起一直担任美敦力公司的高级副总裁兼总裁。在此之前，从2009年8月至2012年11月，她担任糖尿病高级副总裁及总裁；从2008年4月至2009年8月，担任战略与创新高级副总裁；从2004年10月至2008年4月，担任心血管业务部血管内创新副总裁兼总经理。从1991年到2004年，她在美敦力公司担任过多个管理和领导职务，包括公司战略副总裁和血管业务财务部副总裁。
- Catherine Szyman has served as a member of our board of directors since November 2019. Since January 2015 Ms. Szyman has been the Corporate Vice President of Critical Care at Edwards Lifesciences Corp., a public company specializing in artificial heart valves and hemodynamic monitoring. Prior to this, Ms. Szyman worked at Medtronic from August 1991 to December 2014 where she held a number of roles, including President of Global Diabetes, Vice President of Corporate Strategy and Business Developments, Vice President and General Manager for the endovascular business and Vice President of Finance for the vascular business. Ms. Szyman currently serves on the board of director of Endotronix, Inc., a private medical device company, Opus College of Business at the University of St. Thomas and the American Heart Association, a non-profit organization that funds cardiovascular medical research. Ms. Szyman has a B.A. from University of St. Thomas and an M.B.A. from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- William Hoffman
William Hoffman自2015年2月以来一直担任我们的首席执行官兼总裁，并担任我们的董事会成员。Hoffman之前从2008年5月到2014年7月被Medtronic plc（Medtronic）收购，担任Visualase，Inc.（一家专注于MRI引导激光的私人公司）首席执行官。在此之前，Hoffman先生从2006年4月到2007年11月是Rubicor Medical，Inc.的首席运营官，该公司是一家私人公司，专注于微创乳腺活检和肿块切除术技术。Hoffman从2003年7月到2006年2月担任Foxhollow Technologies，Inc.（一家制造用于治疗外周动脉疾病的医疗设备的私营公司）销售主管，然后担任销售Vice President。Hoffman先生目前任职于两家私人公司的董事会:Monteris Medical，Inc.和4C Medical Group。Hoffman先生在迪金森学院（Dickinson College）获得文学学士学位。
William Hoffman has served as our Chief Executive Officer and President and as a member of our board of directors since February 2015. Mr. Hoffman previously served as Chief Executive Officer at Visualase, Inc., a private company focusing on MRI-guided lasers, from May 2008 until its acquisition by Medtronic PLC, or Medtronic, in July 2014. Prior to this, Mr. Hoffman was the Chief Operating Officer of Rubicor Medical, Inc., a private company focusing on minimally invasive breast biopsy and lumpectomy technology, from April 2006 to November 2007. From July 2003 to February 2006 Mr. Hoffman served as Director of Sales and then the Vice President of Sales at FoxHollow Technologies, Inc, a private company that makes medical devices used to treat peripheral artery disease. Mr. Hoffman currently serves on the board of directors of two private companies: Monteris Medical, Inc. and 4C Medical Group. Mr. Hoffman received a B.A. from Dickinson College.- William Hoffman自2015年2月以来一直担任我们的首席执行官兼总裁，并担任我们的董事会成员。Hoffman之前从2008年5月到2014年7月被Medtronic plc（Medtronic）收购，担任Visualase，Inc.（一家专注于MRI引导激光的私人公司）首席执行官。在此之前，Hoffman先生从2006年4月到2007年11月是Rubicor Medical，Inc.的首席运营官，该公司是一家私人公司，专注于微创乳腺活检和肿块切除术技术。Hoffman从2003年7月到2006年2月担任Foxhollow Technologies，Inc.（一家制造用于治疗外周动脉疾病的医疗设备的私营公司）销售主管，然后担任销售Vice President。Hoffman先生目前任职于两家私人公司的董事会:Monteris Medical，Inc.和4C Medical Group。Hoffman先生在迪金森学院（Dickinson College）获得文学学士学位。
- William Hoffman has served as our Chief Executive Officer and President and as a member of our board of directors since February 2015. Mr. Hoffman previously served as Chief Executive Officer at Visualase, Inc., a private company focusing on MRI-guided lasers, from May 2008 until its acquisition by Medtronic PLC, or Medtronic, in July 2014. Prior to this, Mr. Hoffman was the Chief Operating Officer of Rubicor Medical, Inc., a private company focusing on minimally invasive breast biopsy and lumpectomy technology, from April 2006 to November 2007. From July 2003 to February 2006 Mr. Hoffman served as Director of Sales and then the Vice President of Sales at FoxHollow Technologies, Inc, a private company that makes medical devices used to treat peripheral artery disease. Mr. Hoffman currently serves on the board of directors of two private companies: Monteris Medical, Inc. and 4C Medical Group. Mr. Hoffman received a B.A. from Dickinson College.
- Mitchell Hill
Mitchell Hill自2019年3月起担任我们的首席财务官。从2018年6月至2019年2月，希尔先生担任Flow Lighting Technologies，Inc.（一家专注于基于云的软件的私人公司）的首席执行官兼董事会成员。从2017年8月至2018年6月，希尔先生担任Livmor，Inc.（一家私人公司，专注于远程患者监控的数字健康解决方案）的董事会成员。2015年9月至2018年5月，希尔先生担任Ominto，Inc.董事会和审计委员会成员2013年3月至2015年3月，希尔先生担任Alphaeon Corporation（一家为自费医疗领域的梦百合提供商提供服务的私营公司）的执行Vice President兼首席财务官。2015年之前，希尔先生曾在多家公司担任首席财务官，包括Cameron Health，Inc.，VisioGen Inc.，Insight Health Services Holdings Corp.，BMS报销管理公司，Buy.com，Inc.以及Walt Disney Imagineering和迪士尼发展公司。Hill先生在杨百翰大学（Brigham Young University）获得商业会计学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Mitchell Hill has served as our Chief Financial Officer since March 2019. From June 2018 to February 2019 Mr. Hill served as the Chief Executive Officer and as a member of the board of directors of Flow Lighting Technologies, Inc., a private company specializing in cloud-based software. From August 2017 to June 2018 Mr. Hill served as a member of the board of directors of LIVMOR, Inc., a private company focusing on digital health solutions for remote patient monitoring. From September 2015 to May 2018 Mr. Hill served as a member of the board of directors and audit committee of Ominto, Inc. From March 2013 to March 2015 Mr. Hill was the Executive Vice President and Chief Financial Officer of Alphaeon Corporation, a private company serving healthcare providers in the self-pay medical field. Prior to 2015 Mr. Hill served as Chief Financial Officer at a number of companies, including Cameron Health, Inc., Visiogen Inc., Insight Health Services Holdings Corp., BMS Reimbursement Management, Buy.com, Inc. and Walt Disney Imagineering and Disney Development Co. Mr. Hill received his B.S. in Business Accounting from Brigham Young University and an M.B.A. from Harvard Business School.- Mitchell Hill自2019年3月起担任我们的首席财务官。从2018年6月至2019年2月，希尔先生担任Flow Lighting Technologies，Inc.（一家专注于基于云的软件的私人公司）的首席执行官兼董事会成员。从2017年8月至2018年6月，希尔先生担任Livmor，Inc.（一家私人公司，专注于远程患者监控的数字健康解决方案）的董事会成员。2015年9月至2018年5月，希尔先生担任Ominto，Inc.董事会和审计委员会成员2013年3月至2015年3月，希尔先生担任Alphaeon Corporation（一家为自费医疗领域的梦百合提供商提供服务的私营公司）的执行Vice President兼首席财务官。2015年之前，希尔先生曾在多家公司担任首席财务官，包括Cameron Health，Inc.，VisioGen Inc.，Insight Health Services Holdings Corp.，BMS报销管理公司，Buy.com，Inc.以及Walt Disney Imagineering和迪士尼发展公司。Hill先生在杨百翰大学（Brigham Young University）获得商业会计学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Mitchell Hill has served as our Chief Financial Officer since March 2019. From June 2018 to February 2019 Mr. Hill served as the Chief Executive Officer and as a member of the board of directors of Flow Lighting Technologies, Inc., a private company specializing in cloud-based software. From August 2017 to June 2018 Mr. Hill served as a member of the board of directors of LIVMOR, Inc., a private company focusing on digital health solutions for remote patient monitoring. From September 2015 to May 2018 Mr. Hill served as a member of the board of directors and audit committee of Ominto, Inc. From March 2013 to March 2015 Mr. Hill was the Executive Vice President and Chief Financial Officer of Alphaeon Corporation, a private company serving healthcare providers in the self-pay medical field. Prior to 2015 Mr. Hill served as Chief Financial Officer at a number of companies, including Cameron Health, Inc., Visiogen Inc., Insight Health Services Holdings Corp., BMS Reimbursement Management, Buy.com, Inc. and Walt Disney Imagineering and Disney Development Co. Mr. Hill received his B.S. in Business Accounting from Brigham Young University and an M.B.A. from Harvard Business School.
- Andrew Hykes
Andrew Hykes自2017年9月起担任我们的首席商务官。Hykes先生于2012年11月至2017年1月担任Sequent Medical Inc.（Sequent Medical）的商业运营Vice President，Sequent Medical是一家专注于基于导管的神经血管疗法的私营公司，于2016年7月被Terumo Corporation收购。此前，Hykes从2002年8月到2012年10月在Medtronic plc（一家公共医疗设备公司）任职，担任多个职位，包括:市场营销Vice President、临床和监管事务Vice President以及投资者关系主管。从1995年到2000年，Hykes先生在荷兰银行（ABN AMRO Bank）的梦百合银行工作。Hykes先生在威斯康星大学麦迪逊分校（University of Wisconsin Madison）获得工商管理学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Andrew Hykes has served as our Chief Commercial Officer since September 2017. From November 2012 to January 2017 Mr. Hykes was the Vice President of Commercial Operations of Sequent Medical Inc., or Sequent Medical, a private company focused on catheter-based neurovascular therapies that was acquired by Terumo Corporation in July 2016. Prior to this, Mr. Hykes worked for Medtronic PLC, a public medical device company, from August 2002 to October 2012 where he held several positions including: Vice President of Marketing, Vice President of Clinical and Regulatory Affairs and Director of Investor Relations. From 1995 to 2000 Mr. Hykes worked in healthcare banking for ABN AMRO Bank. Mr. Hykes received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School.- Andrew Hykes自2017年9月起担任我们的首席商务官。Hykes先生于2012年11月至2017年1月担任Sequent Medical Inc.（Sequent Medical）的商业运营Vice President，Sequent Medical是一家专注于基于导管的神经血管疗法的私营公司，于2016年7月被Terumo Corporation收购。此前，Hykes从2002年8月到2012年10月在Medtronic plc（一家公共医疗设备公司）任职，担任多个职位，包括:市场营销Vice President、临床和监管事务Vice President以及投资者关系主管。从1995年到2000年，Hykes先生在荷兰银行（ABN AMRO Bank）的梦百合银行工作。Hykes先生在威斯康星大学麦迪逊分校（University of Wisconsin Madison）获得工商管理学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Andrew Hykes has served as our Chief Commercial Officer since September 2017. From November 2012 to January 2017 Mr. Hykes was the Vice President of Commercial Operations of Sequent Medical Inc., or Sequent Medical, a private company focused on catheter-based neurovascular therapies that was acquired by Terumo Corporation in July 2016. Prior to this, Mr. Hykes worked for Medtronic PLC, a public medical device company, from August 2002 to October 2012 where he held several positions including: Vice President of Marketing, Vice President of Clinical and Regulatory Affairs and Director of Investor Relations. From 1995 to 2000 Mr. Hykes worked in healthcare banking for ABN AMRO Bank. Mr. Hykes received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School.
- Thomas Tu
Thomas Tu自2019年7月起担任首席医疗官。从2003年6月至2019年6月，涂博士在肯塔基州路易斯维尔的Baptist Health Hospital从事临床实践，他还担任心脏导管实验室主任。自2010年12月以来，涂博士一直担任World Health Initiative（一家非营利组织，为越南和中国的医院提供医疗和教育计划）的首席执行官兼总裁。涂博士是心血管造影与介入学会的研究员，之前曾担任该学会政治行动委员会和新兴领袖导师计划的主席。涂博士在马萨诸塞州波士顿的马萨诸塞州总医院（Massachusetts General Hospital）和贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成了内科、心脏病学、介入心脏病学、外围干预方面的培训。涂博士获得内科，心血管疾病和介入性心脏病学的董事会认证。Tu博士在弗吉尼亚大学（University of Virginia）获得学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
Thomas Tu has served as our Chief Medical Officer since July 2019. From June 2003 to June 2019 Dr. Tu was in clinical practice at Baptist Health Hospital in Louisville, Kentucky, where he also served as director of the cardiac catheterization laboratory. Since December 2010 Dr. Tu has served as the Chief Executive Officer and President of World Health Initiative, a non-profit organization that provides medical care and educational programs to hospitals in Vietnam and China. Dr. Tu is a fellow of the Society for Cardiovascular Angiography & Interventions and previously served as the chairs of the society’s political action committee and Emerging Leader Mentorship program. Dr. Tu completed his training in internal medicine, cardiology, interventional cardiology, peripheral interventions at Massachusetts General Hospital and Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Tu is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Tu received his B.A. from the University of Virginia and his M.D. from Harvard Medical School.- Thomas Tu自2019年7月起担任首席医疗官。从2003年6月至2019年6月，涂博士在肯塔基州路易斯维尔的Baptist Health Hospital从事临床实践，他还担任心脏导管实验室主任。自2010年12月以来，涂博士一直担任World Health Initiative（一家非营利组织，为越南和中国的医院提供医疗和教育计划）的首席执行官兼总裁。涂博士是心血管造影与介入学会的研究员，之前曾担任该学会政治行动委员会和新兴领袖导师计划的主席。涂博士在马萨诸塞州波士顿的马萨诸塞州总医院（Massachusetts General Hospital）和贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成了内科、心脏病学、介入心脏病学、外围干预方面的培训。涂博士获得内科，心血管疾病和介入性心脏病学的董事会认证。Tu博士在弗吉尼亚大学（University of Virginia）获得学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
- Thomas Tu has served as our Chief Medical Officer since July 2019. From June 2003 to June 2019 Dr. Tu was in clinical practice at Baptist Health Hospital in Louisville, Kentucky, where he also served as director of the cardiac catheterization laboratory. Since December 2010 Dr. Tu has served as the Chief Executive Officer and President of World Health Initiative, a non-profit organization that provides medical care and educational programs to hospitals in Vietnam and China. Dr. Tu is a fellow of the Society for Cardiovascular Angiography & Interventions and previously served as the chairs of the society’s political action committee and Emerging Leader Mentorship program. Dr. Tu completed his training in internal medicine, cardiology, interventional cardiology, peripheral interventions at Massachusetts General Hospital and Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Tu is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Tu received his B.A. from the University of Virginia and his M.D. from Harvard Medical School.